. Introduction {#s01}
==============

It is a widely accepted idea that cancer patients exhibit elevated levels of circulating procoagulants that correlate with the risk of thrombosis, suggesting a potential link between coagulation and cancer development^[@b1]^. In fact, extensive studies showed that coagulation plays an important role in tumor growth, invasion, and metastasis^[@b2]^. Coagulation factor VII (FVII) is an approximately 50-kDa vitamin K-dependent precursor of a serine protease that triggers the extrinsic coagulation cascade^[@b3]^. This protease precursor is produced predominantly in the liver and released into the circulation. Upon injury, FVII interacts with tissue factor (TF), an integral membrane protein that functions as the cellular receptor for FVII, resulting in its conversion to the active form (FVIIa). The TF-FVIIa binary complex then initiates a downstream coagulation cascade, ultimately leading to formation of thrombin. Thrombin subsequently activates platelets for deposition of fibrin, another component of a hemostatic plug. Nevertheless, TF is also often expressed on the surface of cancer cells and tumor vasculature^[@b4]^. Binding of circulating FVIIa to TF also triggers pathways that do not cause blood coagulation but rather activate protease-activated receptor 2 (PAR2) and subsequent signaling events^[@b5]^. The activation of PAR2 is associated with numerous physiological and pathological mechanisms and also drives the production of pro-oncogenic and immunological factors. Additionally, shed membrane-derived vesicles (generally referred to as microparticles) from tumor cells contain TF, which are major contributors of coagulopathy in cancer^[@b6]^.

Hepatocellular carcinoma (HCC) is the fifth most frequent neoplasm worldwide and the third most common cause of tumor-related deaths^[@b7]^. Invasion and metastasis are characteristic features of HCC and the major causes of treatment failure in some cases^[@b8],[@b9]^. Although several target therapies had been developed recently, the overall clinical outcomes remain unsatisfactory. Thus, there is an urgent need for further insights into the molecular mechanisms responsible for the biological behavior of HCC and development of new targets that supplement existing treatment protocols.

Our previous studies revealed that the coagulation pathway actively participates in the autophagic process. FVII, together with TF, negatively regulates autophagy and enhances the invasiveness of HCC through activation of downstream signaling driven by PAR2^[@b10]-[@b12]^. We found that overexpression of FVII in HCC tumor -carries high incidence of recurrence after curative hepatectomy^[@b10],[@b12]^. A mouse xenograft model also showed that FVII increases tumor microvessel density, suggesting that FVII may be involved in vascular invasion, a major prognostic factor of HCC^[@b12]^.

Recent studies have provided evidence that gene polymorphisms are associated with the protein level. Given the implications that FVII levels are linked to malignant progression of HCC, one would expect that FVII polymorphisms may also be a critical participating factor. Three common polymorphisms (--401G/T, --402G/A, --323ins10-bp) in the promoter region of the FVII gene locus have been reported to be associated with circulating levels of FVII^[@b13],[@b14]^. These variants result in differences in promoter activity^[@b15]^. Additionally, the relationship between FVII polymorphisms and tumorigenesis has been observed in breast cancer^[@b16]^. However, whether these gene variants affect the development and progression of HCC has not yet been determined. Therefore, in this study, we investigated the contribution of common functional polymorphisms in the promoter region of FVII gene and discussed their relevance in the development and outcomes of HCC.

. Materials and methods {#s02}
=======================

. Patient samples {#s02.01}
-----------------

Peripheral blood was collected from HCC patients who underwent curative resection for HCC (*n*=37) at Kaohsiung Chang Gung Memorial Hospital. The clinicopathological features are listed in **[Table 1](#Table1){ref-type="table"}**. Healthy donors (*n*=30) were recruited as controls. All controls were free from any medical comorbidities. Written informed consent was obtained from each patient and healthy subject. This study was approved by the Institutional Review Board of Chang Gung Medical Foundation (100-3002A3, 101-1377A3, and 102-5206B). Genomic DNA was extracted using the Genomic DNA Extraction Mini Kit (Favorgen Biotech Corp.; Pingtung, Taiwan).

. Genotyping of FVII polymorphisms {#s02.02}
----------------------------------

A 705-bp DNA fragment was amplified by polymerase chain reaction (PCR) for DNA sequencing using the following specific primers: forward primer 5′-GGCTC ACCTA AGAAA CCAGC-3′ and reverse primer 5′-AAGAA ATTGA ACAGG AGCCG-3′. Four common functional polymorphisms in the promoter region of the FVII gene -- a decanucleotide insertion at position --323 (--323ins10-bp), a G to T substitution at position --401 (--401G/T), a G to A substitution at position --402 (--402G/A), and a T to C substitution at position --122 (--122T/C) -- were analyzed in this study. The PCR reactions started with 2 min at 94 °C for initial denaturation, followed by 30 cycles of 94 °C for 1 min, 60 °C for 1 min, and 72 °C for 1 min. A final extension was carried out at 72 °C for 10 min. DNA sequencing was performed by outsourcing services from Genomics BioSci & Tech, Ltd. (New Taipei City, Taiwan), and distribution of FVII polymorphisms was determined after DNA alignment using BioEdit Sequence Alignment Editor (Ibis Biosciences; Carlsbad, CA, USA).

. Analysis of --402G/A polymorphism of the FVII gene {#s02.03}
----------------------------------------------------

Detection of --402G/A in the FVII promoter was conducted using the TaqMan SNP Genotyping Assays (Thermo Fisher; Waltham, MA, USA). Allele-specific TaqMan fluorescent probes targeting --402G/A and a PCR primer pair were mixed with test samples and analyzed on an ABI 7500 fast PCR system (Applied Biosystems; Grand Island, NY, USA).

. Statistical analysis {#s02.04}
----------------------

The continuous variables were presented as means ± SD, and statistics were performed using Student's *t*-test. The correlations between gene polymorphisms and recurrence-free/overall survival were examined using the Kaplan-Meier method with log rank tests for comparison between both study groups. Other discrete variables were analyzed using the Chi-square test. Differences were considered statistically significant when *P*\<0.05. Statistical analysis was performed using the SPSS software (SPSS Inc.; Chicago, IL, USA).

. Results {#s03}
=========

. Comparison of demographics and blood test levels {#s03.01}
--------------------------------------------------

The mean age at diagnosis of all patients was 55 years (range 37--75 years); 29 patients were male, and 8 were female. The majority of underlying disease was hepatitis B/C. The tumor characteristics are described in **[Table 1](#Table1){ref-type="table"}**. In comparing the basic blood test status between healthy donors and HCC patients, we found that the international normalized ratio, hemoglobin, and hematocrit showed no significant difference. HCC patients were found to have lower platelet counts than healthy donors due to underlying liver cirrhosis and portal hypertension with subsequent thrombocytopenia as expected (**[Table 2](#Table2){ref-type="table"}**).

402G/A was the most frequent FVII polymorphism in both HCC patients and healthy donors {#s03.01-1}
--------------------------------------------------------------------------------------

To assess the frequencies and distribution of four common polymorphisms (--402G/A, --401G/T, --323ins10-bp, and --122T/C) in the FVII gene among HCC patients and healthy controls, DNA sequencing was conducted. Our results revealed that three of the common variants (--401G/T, --323ins10-bp, and --122T/C) were very conserved, showing 100% and 93.75% wild-type homozygous genotypes in healthy donors and HCC patients, respectively (**[Table 3](#Table3){ref-type="table"}**). Interestingly, the --402G/A polymorphism occurred most frequently among studied subjects, with G and A alleles having almost equal frequencies (50%/50% in healthy donors, 55.41%/44.59% in HCC patients) (**[Table 4](#Table4){ref-type="table"}**).

. FVII polymorphisms were not associated with the occurrence of HCC {#s03.02}
-------------------------------------------------------------------

Given that --402G/A was the most frequent FVII polymorphism in HCC patients, we next compared whether there was a prevalence of major polymorphism at this particular site in healthy donors and HCC patients. Our results showed that there was no significant difference in terms of (GG *vs*. GA *vs*. AA) or (GG *vs*. non-GG) between HCC and healthy individuals (**[Table 4](#Table4){ref-type="table"}**), indicating that this FVII polymorphism may not be associated with the development of HCC.

. FVII polymorphisms were not associated with the clinical features and outcomes of HCC {#s03.03}
---------------------------------------------------------------------------------------

We then examined whether there was a correlation between the --402G/A polymorphism and the clinicopathological features of HCC patients. Comparisons between GG and non-GG alleles are shown in **[Table 5](#Table5){ref-type="table"}**. Once again, there was no significant difference among these clinical parameters, indicating that FVII polymorphisms may not play a critical role in regulating pathological features of HCC.

We further assessed the effects of --402G/A polymorphism on HCC outcomes. As shown in **[Figure 1](#Figure1){ref-type="fig"}** (left), there was no significant difference in recurrence-free survival among HCC patients with --402GG, GA, or AA alleles. No association was found when the patients were categorized into --402GG and non-GG groups (**[Figure 1](#Figure1){ref-type="fig"}**, right). Similarly, no significant effects of --402G/A polymorphisms on 3-year overall survival were observed in HCC patients (**[Figure 2](#Figure2){ref-type="fig"}**).

![Kaplan-Meier curves showing cumulative recurrence-free survival of HCC patients who underwent curative resection categorized according to-402GG, GA and AA (left) or -402GG and non-GG (right) genotypes in the FVII promoter region. HCC patients (*n*=37) were followed up after tumor resection. *P* value was calculated using a log-rank test.](cbm-15-3-275-1){#Figure1}

![Cumulative overall survival of patients with resected HCC categorized according to -402GG, GA and AA (left) or -402GG and non-GG (right) genotypes in the FVII promoter region. HCC patients (*n*=37) were followed up for the analysis. *P* value was calculated using a log-rank test.](cbm-15-3-275-2){#Figure2}

. Discussion {#s04}
============

In the current investigation, we aimed to study the correlations between common FVII polymorphisms and incidence/outcomes of HCC. We have previously shown that FVII is highly associated with autophagy and migration in HCC cells and tumor stage, vascular invasion, and recurrence in clinical HCC cases^[@b10]-[@b12]^. Although several other studies found TF as the major deciding factor in the TF-FVII-PAR2 signaling in other cancers, our previous findings suggested that changes in FVII levels were the main contributor to aberrant PAR2 signaling in HCC^[@b12]^, which may partially result from the fact that FVII is principally synthesized in the liver and in close proximity with cell surface-anchored TF and PAR2. However, the polymorphisms examined did not seem to correlate well with the clinical parameters of HCC.

Clinical studies have shown correlations between FVII levels and various human disorders, including cardiovascular diseases and cancer^[@b16]-[@b19]^. We have previously demonstrated that FVII levels are associated with malignant behavior and recurrence in HCC. However, the molecular mechanisms of how hepatic FVII expression is regulated and its reflection on circulating levels are still unknown. Recent studies have provided evidence linking polymorphic markers of the FVII gene with FVII transcriptional activity and plasma protein levels. The --323ins10-bp polymorphism is shown to reduce promoter activity and related to low plasma levels of FVII^[@b13]^. The --401G/T polymorphism is also found to be associated with lower plasma levels, but --402A is related to higher FVII levels compared with the common G allele^[@b14]^. FVII polymorphisms may determine up to about one third of the differences in FVII levels^[@b20]^. However, the influence of these genetic variants on disease risks can be inconsistent. For example, the FVII-lowering --323ins10-bp polymorphism has presented a positive association with total and arterial thrombosis in patients with myeloproliferative neoplasms, while several studies have shown a protective effect on thrombotic events^[@b17],[@b21],[@b22]^. In addition, a number of studies indicate that certain polymorphisms in the FVII gene may contribute to a more hypercoagulable state. However, other studies have failed to find any associations^[@b23],[@b24]^. The discrepancies have not been resolved although cohort selection may have affected the outcome of analysis. In addition, the link between observed polymorphisms and disease mechanisms also remains to be elucidated.

A possible contribution of altered --402G/A genotype and allele frequency in the FVII gene has been implicated in breast cancer over control cases^[@b16]^. In our study, there was no significant difference in the distribution of --402G/A or any other genotype among HCC cases versus control subjects. The lack of association between FVII polymorphisms and clinical parameters and prognosis of HCC may be due to the relatively small size of the cohort. However, several interesting findings can be concluded based on our results. First, the incidence of the "rare" --402A allele was nearly equal to that of --402G, which is distinct from other studies. Furthermore, almost only wild-type genotypes (but one HCC case) were observed for --401G/T, --122T/C, and --323ins10-bp in both control and HCC subjects. The underlying cause of these observations is currently unknown. Further studies with a larger series need to be conducted before reaching more precise conclusions. It is also important to associate the observed polymorphisms with plasma FVII levels and TMN stages of enrolled HCC patients. Additional clinical parameters should also be included besides recurrence and survival rate in future studies.

. Conclusions {#s05}
=============

In conclusion, our data indicate that the four common polymorphisms (--122T/C, --323ins10-bp, --401G/T, and --402G/A) in the promoter region of the FVII gene are not contributing factors to incidence, recurrence, and survival in HCC patients. In addition, --402G/A is the most common variant of FVII in both control and HCC subjects, while others present almost no variations. As HCC is a consequence of multifactorial events, apart from the classic biological factors that are often discussed in the literature^[@b25]^, our study is the first attempt to demonstrate the association of FVII polymorphisms with the presence of HCC. From our results, there may be other or even unidentified polymorphic variants in the FVII gene that are related to HCC, although further studies are needed to confirm this.
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###### 

Clinico-pathological features of 37 patients with HCC undergoing hepatectomy

  Iterm                                  Value
  -------------------------------------- ---------------------
  Patient demographics                   
  　Age (years) (median; range)          55 (37--75)
  　Sex (male : female)                  29: 8
  　AFP (ng/mL) (median; range)          24.9 (1.99--303145)
  　Multiple tumor (+) (%)               9 (24.32%)
  　Tumor size (cm) (median; range)^a^   3.5 (1--19.3)
  　Liver cirrhosis (+) (%)              18 (48.65%)
  　Hepatitis (B : C : B+C : none)       23: 6: 0: 8
  　TNM stage (I : II : III)^b^          7: 19: 9
  　Hypertension (+) (%)                 9 (24.3%)
  　Diabetes mellitus (+) (%)            9 (24.3%)
  　Ischemic heart disease (+) (%)       0 (0%)
  Pathological features                  
  　Capsule (yes : no)                   6: 28
  　Satellite nodule (yes : no)          5: 30
  　Microvascular invasion (yes : no)    25: 10
  　Histological grade (I : II : III)    5: 27: 1

###### 

Comparison of basic information in healthy donors and HCC patients

  Variable                         HCC (*n*=37)     Donors (*n*=30)   *P*
  -------------------------------- ---------------- ----------------- -----------
  Age (years) (median; range)      55 (37--75)      29 (20--54)       \<.0001\*
  Sex (male : female)              29:8             15:15             0.030\*
  INR (mean±SD)                    1.03±0.06        1.04±0.08         0.759
  Hemoglobin (g/dL) (mean±SD)      13.82±1.95       13.01±1.53        0.067
  Hematocrit (%) (mean±SD)         41.35±5.47       39.3±4.13         0.093
  Platelet (1000/μL) (mean±SD)     190.14±84.33\*   259.47±62.82      \<0.001\*
  Hypertension (+) (%)             0                9 (24.3%)         \-
  Diabetes mellitus (+) (%)        0                9 (24.3%)         \-
  Ischemic heart disease (+) (%)   0                0                 \-

###### 

Distribution of three common polymorphisms, --401 G/T, --323 ins 10-bp, and --122 T/C of FVII gene in HCC patients and healthy donors

  FVII polymorphism   Donors (*n*=5)   HCC (*n*=16)   *P*
  ------------------- ---------------- -------------- -------
  --401G/T                                            0.597
  　GG                5 (100%)         15 (93.75%)    
  　GT                0 (0%)           1 (6.25%)      
  　TT                0 (0%)           0 (0%)         
  　G allele          100%             96.88%         
  　T allele          0%               3.13%          
  --323ins10-bp                                       0.597
  　w/w               5 (100%)         15 (93.75%)    
  　ins/w             0 (0%)           1 (6.25%)      
  　ins/ins           0 (0%)           0 (0%)         
  　w allele          100%             96.88%         
  　ins allele        0%               3.13%          
  --122T/C                                            0.597
  　TT                5 (100%)         15 (93.75%)    
  　TC                0 (0%)           1 (6.25%)      
  　CC                0 (0%)           0 (0%)         
  　T allele          100%             96.88%         
  　C allele          0%               3.13%          　

###### 

Comparison of pathological features between SNP-positive and -negative at --402 of FVII promoter in HCC patients

  Variable                 --402 SNP type   *P*        
  ------------------------ ---------------- ----- ---- -------
  Age (years)                                          1.000
  　≥ 50                   25               9     16   
  　\< 50                  12               5     7    
  Sex                                                  0.700
  　Male                   29               11    18   
  　Female                 8                3     5    
  AFP (ng/mL)                                          0.840
  　\< 20                  18               7     11   
  　≥ 20                   19               7     12   
  Tumor size (cm)                                      0.120
  　≥ 5 cm                 14               8     6    
  　\< 5 cm                23               6     17   
  Liver cirrhosis                                      0.640
  　Present                18               8     10   
  　Absent                 19               6     13   
  Hepatitis                                            0.930
  　B                      23               8     15   
  　C                      6                3     3    
  　B+C                    0                0     0    
  　NBNC                   8                3     5    
  TNM stage                                            0.300
  　I                      7                1     6    
  　II                     19               9     10   
  　III                    9                4     5    
  Pathological features                                1.000
  Capsule                                              
  　Present                6                2     4    
  　Absent                 28               12    16   
  Satellite nodule                                     0.624
  　Present                5                2     3    
  　Absent                 30               12    18   
  Microvascular invasion                               0.699
  　Present                25               10    15   
  　Absent                 10               4     6    
  Histological grade                                   0.345
  　I                      5                1     4    
  　II                     27               13    14   
  　III                    1                0     1    

###### 

Distribution of polymorphism --402 G/A of FVII gene in HCC patients and healthy donors

  FVII polymorphism   Donors (*n*=30)   HCC (*n*=37)   *P*
  ------------------- ----------------- -------------- -------
  --402G/A                                             
  　GG                7 (23.3%)         14 (37.8%)     0.291
  　GA                16 (53.4%)        13 (35.2%)     
  　AA                7 (23.3%)         10 (27%)       
  　G allele          50%               55.41%         
  　T allele          50%               44.59%         　
  　GG                7 (23.3%)         14 (37.9%)     0.312
  　Non-GG            23 (76.7)         23 (62.2%)     
